Saturday, October 31, 2026

Redfin Stock Went Down By Over 15% In The Last 5 Sessions

Redfin Stock Went Down By Over 15% In The Last 5 Sessions

(VIANEWS) - Shares of Redfin (NASDAQ: RDFN) slid by a staggering 15.01% in 5 sessions from $9.11 at -15.01, to $7.74 at 11:43 EST on Tuesday, following the last session's downward trend. NASDAQ is falling 0.79% to $11,941.99, following the last session's downward trend.

Redfin's last close was $8.46, 44.16% under its 52-week high of $15.15.

About Redfin

Redfin Corporation operates as a residential real estate brokerage company in the United States and Canada. The company operates an online real estate marketplace and provides real estate services, including assisting individuals in the purchase or sell of home. It also provides title and settlement services; and originates and sells mortgages. The company was formerly known as Appliance Computing Inc. and changed its name to Redfin Corporation in May 2006. Redfin Corporation was incorporated in 2002 and is headquartered in Seattle, Washington.

Earnings Per Share

As for profitability, Redfin has a trailing twelve months EPS of $-2.99.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -141.6%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 25.4%, now sitting on 2.28B for the twelve trailing months.

Moving Average

Redfin's worth is under its 50-day moving average of $8.33 and higher than its 200-day moving average of $7.12.

Volume

Today's last reported volume for Redfin is 1383521 which is 64.49% below its average volume of 3877040.

More news about Redfin (RDFN).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com